Korro Bio (NASDAQ:KRRO – Get Free Report) and BeOne Medicines (NASDAQ:ONC – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, earnings and valuation.
Analyst Recommendations
This is a summary of recent ratings for Korro Bio and BeOne Medicines, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Korro Bio | 1 | 2 | 6 | 3 | 2.92 |
| BeOne Medicines | 1 | 2 | 11 | 2 | 2.88 |
Korro Bio presently has a consensus target price of $16.71, suggesting a potential upside of 47.26%. BeOne Medicines has a consensus target price of $394.00, suggesting a potential upside of 21.98%. Given Korro Bio’s stronger consensus rating and higher possible upside, analysts clearly believe Korro Bio is more favorable than BeOne Medicines.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Korro Bio | $6.39 million | 25.61 | -$117.26 million | ($11.67) | -0.97 |
| BeOne Medicines | $5.34 billion | 6.63 | $286.93 million | $4.47 | 72.26 |
BeOne Medicines has higher revenue and earnings than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Korro Bio and BeOne Medicines’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Korro Bio | -1,834.48% | -117.86% | -71.04% |
| BeOne Medicines | 8.94% | 12.06% | 6.69% |
Risk & Volatility
Korro Bio has a beta of 3.04, suggesting that its share price is 204% more volatile than the S&P 500. Comparatively, BeOne Medicines has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500.
Insider & Institutional Ownership
13.2% of Korro Bio shares are owned by institutional investors. Comparatively, 48.5% of BeOne Medicines shares are owned by institutional investors. 4.8% of Korro Bio shares are owned by insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
BeOne Medicines beats Korro Bio on 10 of the 15 factors compared between the two stocks.
About Korro Bio
Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
About BeOne Medicines
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
Receive News & Ratings for Korro Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Korro Bio and related companies with MarketBeat.com's FREE daily email newsletter.
